CY1107786T1 - Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv - Google Patents

Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv

Info

Publication number
CY1107786T1
CY1107786T1 CY20071101408T CY071101408T CY1107786T1 CY 1107786 T1 CY1107786 T1 CY 1107786T1 CY 20071101408 T CY20071101408 T CY 20071101408T CY 071101408 T CY071101408 T CY 071101408T CY 1107786 T1 CY1107786 T1 CY 1107786T1
Authority
CY
Cyprus
Prior art keywords
vaccinase
rsv
recoverable
vaccines
expression systems
Prior art date
Application number
CY20071101408T
Other languages
English (en)
Inventor
Hong Jin
Roderick Tang
Shengqiang Li
Martin Bryant
Original Assignee
Medimmune Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines, Inc. filed Critical Medimmune Vaccines, Inc.
Publication of CY1107786T1 publication Critical patent/CY1107786T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε γενετικά τροποποιημένους ανασυνδυασμένους συγκυτιακούς αναπνευστικούς ιούς και φορείς ιού οι οποίοι περιέχουν διαγραφές διαφόρων βοηθητικών γονιδίων μεμονωμένα ή σε συνδυασμό. Σύμφωνα με την παρούσα εφεύρεση, οι ανασυνδυασμένοι φορείς συγκυτιακού αναπνευστικού ιού ή ιοί είναι τροποποιημένοι ώστε να περιέχουν πλήρεις διαγραφές των βοηθητικών γονιδίων Μ2-2, NS1, NS2 ή SH ή διαφόρων συνδυασμών τους. Επί πλέον, η παρούσα εφεύρεση αναφέρεται στην εξασθένηση του συγκυτιακού αναπνευστικού ιού δια μεταλλαξιογονίας του γονιδίου Μ2-1.
CY20071101408T 2000-11-28 2007-11-01 Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv CY1107786T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72441600A 2000-11-28 2000-11-28
EP01986054A EP1480671B1 (en) 2000-11-28 2001-11-28 Recombinant rsv virus expression systems and vaccines

Publications (1)

Publication Number Publication Date
CY1107786T1 true CY1107786T1 (el) 2013-06-19

Family

ID=24910360

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101408T CY1107786T1 (el) 2000-11-28 2007-11-01 Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv

Country Status (11)

Country Link
EP (2) EP1920783A1 (el)
JP (2) JP4268407B2 (el)
AT (1) ATE369148T1 (el)
AU (2) AU3652202A (el)
CA (2) CA2430115C (el)
CY (1) CY1107786T1 (el)
DE (1) DE60129860T2 (el)
DK (1) DK1480671T3 (el)
ES (1) ES2291370T3 (el)
PT (1) PT1480671E (el)
WO (1) WO2002044334A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430115C (en) * 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
IL157003A0 (en) 2001-01-19 2004-02-08 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
EP1441762A1 (en) 2001-09-28 2004-08-04 University Of South Florida Rsv gene expression vaccine
CN1646684B (zh) 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
WO2004028478A2 (en) * 2002-09-27 2004-04-08 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
DE602004027362D1 (de) 2003-03-28 2010-07-08 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
WO2012167139A2 (en) * 2011-06-01 2012-12-06 The Board Of Regents For Oklahoma State University Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
EP2718445B1 (en) * 2011-06-08 2023-08-09 Vishwas Joshi A two plasmid mammalian expression system for production of recombinant proteins and viruses
JP6132420B2 (ja) * 2011-10-25 2017-05-24 国立大学法人岐阜大学 変異狂犬病ウイルス合成・増殖方法、並びに狂犬病ワクチン製剤
EP3386539A1 (en) * 2015-12-11 2018-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains with mutations in the m2-2 orf providing a range of attenuation phenotypes
CN115725657A (zh) * 2022-09-16 2023-03-03 中国科学院广州生物医药与健康研究院 一种节段化的水泡性口炎病毒载体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
AU727923B2 (en) * 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
BRPI9710363B8 (pt) * 1996-07-15 2021-07-06 Us Gov Health & Human Serv partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
AU5918100A (en) * 1999-07-09 2001-01-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
CA2430115C (en) * 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines

Also Published As

Publication number Publication date
DE60129860T2 (de) 2008-04-24
EP1480671B1 (en) 2007-08-08
WO2002044334A2 (en) 2002-06-06
PT1480671E (pt) 2007-11-20
EP1920783A1 (en) 2008-05-14
DE60129860D1 (de) 2007-09-20
CA2797703A1 (en) 2002-06-06
EP1480671A4 (en) 2005-06-01
JP2004534514A (ja) 2004-11-18
JP2009028041A (ja) 2009-02-12
JP4268407B2 (ja) 2009-05-27
CA2430115C (en) 2013-02-26
DK1480671T3 (da) 2007-12-10
AU3652202A (en) 2002-06-11
ATE369148T1 (de) 2007-08-15
ES2291370T3 (es) 2008-03-01
EP1480671A2 (en) 2004-12-01
WO2002044334A3 (en) 2004-08-26
AU2002236522B2 (en) 2007-10-25
CA2430115A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
CY1107786T1 (el) Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE417097T1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
DK1086207T3 (da) Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
EA200300810A1 (ru) Вирус, вызывающий заболевание дыхательных путей у восприимчивых млекопитающих
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
CY1109012T1 (el) Παραγωγα νουκλεοσιδιου σαν αναστολεις της rna-εξαρτωμενης rna iϊκης πολυμepασης
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
WO2005023290A3 (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
BR0108499A (pt) Agente terapêutico para hepatite c
ATE375804T1 (de) Ribavirin-enthaltende vakzine
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
DE60040289D1 (de) Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
WO2004028478A3 (en) Functional mutations in respiratory syncytial virus
MXPA03000278A (es) Uso de cepas de parapoxvirus ovis frente a fibrosis de organos.
ITRM20010336A0 (it) Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
CY1113987T1 (el) Τροποποιημενα νουκλεοσιδια για τη θεραπεια ιικων μολυνσεων και του μη κανονικου κυτταρικου πολλαπλασιασμου